Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease

Am J Respir Cell Mol Biol. 2004 Oct;31(4):470-7. doi: 10.1165/rcmb.2004-0090OC. Epub 2004 Jul 15.

Abstract

A beryllium (Be)-ferritin adduct containing 270 pm of Be stimulated proliferation of bronchoalveolar lavage (BAL) lymphocytes from subjects with chronic beryllium disease (CBD) at concentrations 5-6 logs lower than the amounts of beryllium sulfate (BeSO4) needed to induce proliferation. We observed increased apoptotic CBD BAL macrophages after exposure to both BeSO4 (50 +/- 6%, mean +/- SEM, P <0.05 versus unstimulated controls) and Be-ferritin (40 +/- 2%), whereas only 2.0 +/- 0.2% of BAL lymphocytes underwent activation-induced cell death. Be-ferritin also induced apoptosis in BAL macrophages from subjects with Be sensitization (25 +/- 3%) and in the H36.12j hybrid macrophage cell line (15 +/- 2%). Be-ferritin induced lung macrophage CD95 (Fas) expression and the activation of intracellular caspase-3, -8 and -9. Thus, lung macrophages take up Be-ferritin, delivering physiologically relevant levels of Be that promote Be antigen presentation and macrophage apoptosis. Be-ferritin thereby serves as a "Trojan Horse," triggering proliferation of Be-ferritin-specific CBD BAL T cells. We hypothesize that Be-ferritin exposure may result in persistent antigen exposure inducing Be-specific T cell clonal expansion and T cell helper type 1-type cytokine production and potentially explains the chronicity of CBD and its development years after environmental Be exposure has ceased.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antigen Presentation
  • Apoptosis / drug effects*
  • Berylliosis / blood
  • Berylliosis / etiology*
  • Berylliosis / pathology
  • Beryllium / adverse effects
  • Beryllium / pharmacology*
  • Bronchoalveolar Lavage Fluid / cytology
  • Cell Division / drug effects
  • Cell Line
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Female
  • Ferritins / adverse effects
  • Ferritins / pharmacology*
  • Humans
  • Lung / cytology
  • Lung / immunology
  • Lung / metabolism
  • Lymphocyte Activation / drug effects
  • Lymphocytes / cytology
  • Lymphocytes / drug effects*
  • Lymphocytes / immunology
  • Macrophages, Alveolar / cytology
  • Macrophages, Alveolar / drug effects*
  • Macrophages, Alveolar / metabolism
  • Male
  • Middle Aged
  • Occupational Exposure / adverse effects
  • Phagocytes / cytology
  • Phagocytes / drug effects
  • Phagocytes / metabolism
  • Radioisotopes
  • Smoking / drug therapy
  • Smoking / immunology
  • Smoking / metabolism
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • fas Receptor / metabolism

Substances

  • Radioisotopes
  • fas Receptor
  • Ferritins
  • Beryllium